nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3B—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	0.0201	0.112	CbGpPWpGaD
Lithium—GSK3B—IL17 signaling pathway—IL17A—ankylosing spondylitis	0.0122	0.068	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.00774	0.0431	CbGpPWpGaD
Lithium—Blindness—Dexamethasone—ankylosing spondylitis	0.00653	0.00796	CcSEcCtD
Lithium—Optic neuritis—Triamcinolone—ankylosing spondylitis	0.00648	0.00789	CcSEcCtD
Lithium—Optic neuritis—Methylprednisolone—ankylosing spondylitis	0.00646	0.00787	CcSEcCtD
Lithium—Folliculitis—Triamcinolone—ankylosing spondylitis	0.00634	0.00772	CcSEcCtD
Lithium—Folliculitis—Methylprednisolone—ankylosing spondylitis	0.00632	0.00771	CcSEcCtD
Lithium—GSK3B—Validated transcriptional targets of deltaNp63 isoforms—IL1A—ankylosing spondylitis	0.00598	0.0333	CbGpPWpGaD
Lithium—Optic neuritis—Dexamethasone—ankylosing spondylitis	0.00588	0.00716	CcSEcCtD
Lithium—Optic neuritis—Betamethasone—ankylosing spondylitis	0.00588	0.00716	CcSEcCtD
Lithium—Folliculitis—Betamethasone—ankylosing spondylitis	0.00575	0.00701	CcSEcCtD
Lithium—Folliculitis—Dexamethasone—ankylosing spondylitis	0.00575	0.00701	CcSEcCtD
Lithium—Hypercalcaemia—Methylprednisolone—ankylosing spondylitis	0.00572	0.00697	CcSEcCtD
Lithium—GSK3B—Leptin signaling pathway—IL1RN—ankylosing spondylitis	0.00572	0.0319	CbGpPWpGaD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.00553	0.0308	CbGpPWpGaD
Lithium—GSK3B—IL-6 signaling pathway—CRP—ankylosing spondylitis	0.00537	0.0299	CbGpPWpGaD
Lithium—Optic neuritis—Prednisone—ankylosing spondylitis	0.00512	0.00624	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00507	0.0282	CbGpPWpGaD
Lithium—Glycosuria—Triamcinolone—ankylosing spondylitis	0.00492	0.00599	CcSEcCtD
Lithium—Glycosuria—Methylprednisolone—ankylosing spondylitis	0.00491	0.00598	CcSEcCtD
Lithium—Hypothyroidism—Prednisone—ankylosing spondylitis	0.0049	0.00598	CcSEcCtD
Lithium—GSK3A—DAP12 interactions—HLA-C—ankylosing spondylitis	0.00448	0.025	CbGpPWpGaD
Lithium—Glycosuria—Dexamethasone—ankylosing spondylitis	0.00446	0.00544	CcSEcCtD
Lithium—Glycosuria—Betamethasone—ankylosing spondylitis	0.00446	0.00544	CcSEcCtD
Lithium—Leukocytosis—Methylprednisolone—ankylosing spondylitis	0.00423	0.00515	CcSEcCtD
Lithium—Folliculitis—Methotrexate—ankylosing spondylitis	0.00418	0.0051	CcSEcCtD
Lithium—Psoriasis—Methotrexate—ankylosing spondylitis	0.00418	0.0051	CcSEcCtD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.00409	0.0228	CbGpPWpGaD
Lithium—Memory impairment—Prednisone—ankylosing spondylitis	0.00401	0.00489	CcSEcCtD
Lithium—Glycosuria—Prednisone—ankylosing spondylitis	0.00388	0.00474	CcSEcCtD
Lithium—Leukocytosis—Dexamethasone—ankylosing spondylitis	0.00385	0.00469	CcSEcCtD
Lithium—Leukocytosis—Betamethasone—ankylosing spondylitis	0.00385	0.00469	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00375	0.0209	CbGpPWpGaD
Lithium—Stupor—Methotrexate—ankylosing spondylitis	0.00352	0.00429	CcSEcCtD
Lithium—Skin ulcer—Methotrexate—ankylosing spondylitis	0.00338	0.00412	CcSEcCtD
Lithium—Leukocytosis—Prednisone—ankylosing spondylitis	0.00335	0.00408	CcSEcCtD
Lithium—GSK3B—DAP12 interactions—HLA-C—ankylosing spondylitis	0.00331	0.0184	CbGpPWpGaD
Lithium—IMPA2—Metabolism—B3GNT2—ankylosing spondylitis	0.00317	0.0176	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—CD79A—ankylosing spondylitis	0.00316	0.0176	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	0.00315	0.0175	CbGpPWpGaD
Lithium—GSK3A—Immune System—KIR3DL1—ankylosing spondylitis	0.00308	0.0171	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00291	0.0162	CbGpPWpGaD
Lithium—Dry skin—Prednisolone—ankylosing spondylitis	0.00288	0.00351	CcSEcCtD
Lithium—Oliguria—Methotrexate—ankylosing spondylitis	0.00285	0.00348	CcSEcCtD
Lithium—IMPA1—Metabolism—B3GNT2—ankylosing spondylitis	0.00282	0.0157	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.0028	0.0156	CbGpPWpGaD
Lithium—Dysarthria—Methotrexate—ankylosing spondylitis	0.00278	0.00339	CcSEcCtD
Lithium—GSK3A—Innate Immune System—CARD9—ankylosing spondylitis	0.00277	0.0154	CbGpPWpGaD
Lithium—Muscular weakness—Prednisolone—ankylosing spondylitis	0.00277	0.00338	CcSEcCtD
Lithium—Lethargy—Betamethasone—ankylosing spondylitis	0.00268	0.00326	CcSEcCtD
Lithium—Lethargy—Dexamethasone—ankylosing spondylitis	0.00268	0.00326	CcSEcCtD
Lithium—GSK3A—DAP12 interactions—HLA-B—ankylosing spondylitis	0.00265	0.0148	CbGpPWpGaD
Lithium—Muscular weakness—Triamcinolone—ankylosing spondylitis	0.00255	0.00311	CcSEcCtD
Lithium—Muscular weakness—Methylprednisolone—ankylosing spondylitis	0.00254	0.0031	CcSEcCtD
Lithium—Depressed level of consciousness—Methotrexate—ankylosing spondylitis	0.00254	0.0031	CcSEcCtD
Lithium—GSK3B—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	0.00248	0.0138	CbGpPWpGaD
Lithium—Weight increased—Prednisolone—ankylosing spondylitis	0.00247	0.00301	CcSEcCtD
Lithium—Dry skin—Dexamethasone—ankylosing spondylitis	0.0024	0.00293	CcSEcCtD
Lithium—Dry skin—Betamethasone—ankylosing spondylitis	0.0024	0.00293	CcSEcCtD
Lithium—Coma—Methotrexate—ankylosing spondylitis	0.0024	0.00293	CcSEcCtD
Lithium—Urine output increased—Methotrexate—ankylosing spondylitis	0.00238	0.0029	CcSEcCtD
Lithium—GSK3B—B Cell Activation—CD79A—ankylosing spondylitis	0.00234	0.013	CbGpPWpGaD
Lithium—Lethargy—Prednisone—ankylosing spondylitis	0.00233	0.00284	CcSEcCtD
Lithium—Muscular weakness—Dexamethasone—ankylosing spondylitis	0.00231	0.00282	CcSEcCtD
Lithium—Muscular weakness—Betamethasone—ankylosing spondylitis	0.00231	0.00282	CcSEcCtD
Lithium—Weight increased—Triamcinolone—ankylosing spondylitis	0.00227	0.00277	CcSEcCtD
Lithium—GSK3B—Immune System—KIR3DL1—ankylosing spondylitis	0.00227	0.0127	CbGpPWpGaD
Lithium—Weight increased—Methylprednisolone—ankylosing spondylitis	0.00227	0.00277	CcSEcCtD
Lithium—Bradycardia—Prednisolone—ankylosing spondylitis	0.00221	0.0027	CcSEcCtD
Lithium—Polyuria—Methotrexate—ankylosing spondylitis	0.00217	0.00265	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00215	0.012	CbGpPWpGaD
Lithium—GSK3A—Disease—ANTXR2—ankylosing spondylitis	0.00215	0.012	CbGpPWpGaD
Lithium—Dry skin—Prednisone—ankylosing spondylitis	0.00209	0.00255	CcSEcCtD
Lithium—Weight increased—Dexamethasone—ankylosing spondylitis	0.00206	0.00252	CcSEcCtD
Lithium—Weight increased—Betamethasone—ankylosing spondylitis	0.00206	0.00252	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—B3GNT2—ankylosing spondylitis	0.00206	0.0115	CbGpPWpGaD
Lithium—Weight decreased—Betamethasone—ankylosing spondylitis	0.00205	0.0025	CcSEcCtD
Lithium—Weight decreased—Dexamethasone—ankylosing spondylitis	0.00205	0.0025	CcSEcCtD
Lithium—GSK3B—Innate Immune System—CARD9—ankylosing spondylitis	0.00205	0.0114	CbGpPWpGaD
Lithium—Hyperglycaemia—Betamethasone—ankylosing spondylitis	0.00205	0.00249	CcSEcCtD
Lithium—Hyperglycaemia—Dexamethasone—ankylosing spondylitis	0.00205	0.00249	CcSEcCtD
Lithium—Bradycardia—Triamcinolone—ankylosing spondylitis	0.00204	0.00248	CcSEcCtD
Lithium—Bradycardia—Methylprednisolone—ankylosing spondylitis	0.00203	0.00248	CcSEcCtD
Lithium—Muscular weakness—Prednisone—ankylosing spondylitis	0.00201	0.00246	CcSEcCtD
Lithium—GSK3B—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.002	0.0111	CbGpPWpGaD
Lithium—Hallucination—Methylprednisolone—ankylosing spondylitis	0.00199	0.00242	CcSEcCtD
Lithium—GSK3B—DAP12 interactions—HLA-B—ankylosing spondylitis	0.00196	0.0109	CbGpPWpGaD
Lithium—Lethargy—Methotrexate—ankylosing spondylitis	0.00195	0.00237	CcSEcCtD
Lithium—Arrhythmia—Prednisolone—ankylosing spondylitis	0.00194	0.00237	CcSEcCtD
Lithium—GSK3A—Immune System—IL1R2—ankylosing spondylitis	0.00186	0.0104	CbGpPWpGaD
Lithium—Bradycardia—Betamethasone—ankylosing spondylitis	0.00185	0.00225	CcSEcCtD
Lithium—Bradycardia—Dexamethasone—ankylosing spondylitis	0.00185	0.00225	CcSEcCtD
Lithium—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.00182	0.00222	CcSEcCtD
Lithium—Hallucination—Betamethasone—ankylosing spondylitis	0.00181	0.0022	CcSEcCtD
Lithium—Hallucination—Dexamethasone—ankylosing spondylitis	0.00181	0.0022	CcSEcCtD
Lithium—Weight increased—Prednisone—ankylosing spondylitis	0.0018	0.00219	CcSEcCtD
Lithium—Ataxia—Methotrexate—ankylosing spondylitis	0.0018	0.00219	CcSEcCtD
Lithium—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.00179	0.00218	CcSEcCtD
Lithium—Weight decreased—Prednisone—ankylosing spondylitis	0.00179	0.00218	CcSEcCtD
Lithium—Vision blurred—Prednisolone—ankylosing spondylitis	0.00178	0.00217	CcSEcCtD
Lithium—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.00178	0.00217	CcSEcCtD
Lithium—Hyperglycaemia—Prednisone—ankylosing spondylitis	0.00178	0.00217	CcSEcCtD
Lithium—GSK3A—Immune System—ERAP1—ankylosing spondylitis	0.00177	0.00984	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HLA-C—ankylosing spondylitis	0.00174	0.0097	CbGpPWpGaD
Lithium—Angioedema—Prednisolone—ankylosing spondylitis	0.00173	0.00211	CcSEcCtD
Lithium—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.00171	0.00208	CcSEcCtD
Lithium—Vertigo—Prednisolone—ankylosing spondylitis	0.0017	0.00207	CcSEcCtD
Lithium—Syncope—Prednisolone—ankylosing spondylitis	0.0017	0.00207	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00167	0.00932	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.00166	0.00203	CcSEcCtD
Lithium—Convulsion—Prednisolone—ankylosing spondylitis	0.00164	0.002	CcSEcCtD
Lithium—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.00162	0.00198	CcSEcCtD
Lithium—Arrhythmia—Betamethasone—ankylosing spondylitis	0.00162	0.00198	CcSEcCtD
Lithium—GSK3A—Immune System—CARD9—ankylosing spondylitis	0.00162	0.009	CbGpPWpGaD
Lithium—Bradycardia—Prednisone—ankylosing spondylitis	0.00161	0.00196	CcSEcCtD
Lithium—Alopecia—Betamethasone—ankylosing spondylitis	0.0016	0.00195	CcSEcCtD
Lithium—Alopecia—Dexamethasone—ankylosing spondylitis	0.0016	0.00195	CcSEcCtD
Lithium—Discomfort—Prednisolone—ankylosing spondylitis	0.00159	0.00194	CcSEcCtD
Lithium—Angioedema—Triamcinolone—ankylosing spondylitis	0.00159	0.00194	CcSEcCtD
Lithium—GSK3B—Disease—ANTXR2—ankylosing spondylitis	0.00159	0.00886	CbGpPWpGaD
Lithium—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00159	0.00193	CcSEcCtD
Lithium—Hallucination—Prednisone—ankylosing spondylitis	0.00157	0.00192	CcSEcCtD
Lithium—Vertigo—Triamcinolone—ankylosing spondylitis	0.00156	0.00191	CcSEcCtD
Lithium—Syncope—Triamcinolone—ankylosing spondylitis	0.00156	0.0019	CcSEcCtD
Lithium—Vertigo—Methylprednisolone—ankylosing spondylitis	0.00156	0.0019	CcSEcCtD
Lithium—Syncope—Methylprednisolone—ankylosing spondylitis	0.00156	0.0019	CcSEcCtD
Lithium—Oedema—Prednisolone—ankylosing spondylitis	0.00155	0.00188	CcSEcCtD
Lithium—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.00153	0.00187	CcSEcCtD
Lithium—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.00153	0.00186	CcSEcCtD
Lithium—Shock—Prednisolone—ankylosing spondylitis	0.00152	0.00185	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.00152	0.00185	CcSEcCtD
Lithium—Convulsion—Triamcinolone—ankylosing spondylitis	0.00151	0.00184	CcSEcCtD
Lithium—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00151	0.00183	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—IL1A—ankylosing spondylitis	0.0015	0.00838	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TNF—ankylosing spondylitis	0.00149	0.00832	CbGpPWpGaD
Lithium—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.00148	0.0018	CcSEcCtD
Lithium—Drowsiness—Methotrexate—ankylosing spondylitis	0.00147	0.00179	CcSEcCtD
Lithium—Discomfort—Triamcinolone—ankylosing spondylitis	0.00146	0.00179	CcSEcCtD
Lithium—Discomfort—Methylprednisolone—ankylosing spondylitis	0.00146	0.00178	CcSEcCtD
Lithium—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00145	0.00177	CcSEcCtD
Lithium—Angioedema—Betamethasone—ankylosing spondylitis	0.00144	0.00176	CcSEcCtD
Lithium—Angioedema—Dexamethasone—ankylosing spondylitis	0.00144	0.00176	CcSEcCtD
Lithium—Confusional state—Methylprednisolone—ankylosing spondylitis	0.00143	0.00174	CcSEcCtD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.00142	0.00792	CbGpPWpGaD
Lithium—Oedema—Triamcinolone—ankylosing spondylitis	0.00142	0.00173	CcSEcCtD
Lithium—Vertigo—Dexamethasone—ankylosing spondylitis	0.00142	0.00173	CcSEcCtD
Lithium—Vertigo—Betamethasone—ankylosing spondylitis	0.00142	0.00173	CcSEcCtD
Lithium—Syncope—Dexamethasone—ankylosing spondylitis	0.00142	0.00173	CcSEcCtD
Lithium—Syncope—Betamethasone—ankylosing spondylitis	0.00142	0.00173	CcSEcCtD
Lithium—Arrhythmia—Prednisone—ankylosing spondylitis	0.00141	0.00172	CcSEcCtD
Lithium—Shock—Triamcinolone—ankylosing spondylitis	0.0014	0.0017	CcSEcCtD
Lithium—Alopecia—Prednisone—ankylosing spondylitis	0.0014	0.0017	CcSEcCtD
Lithium—Shock—Methylprednisolone—ankylosing spondylitis	0.00139	0.0017	CcSEcCtD
Lithium—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.00139	0.00169	CcSEcCtD
Lithium—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.00139	0.00169	CcSEcCtD
Lithium—GSK3B—Immune System—IL1R2—ankylosing spondylitis	0.00138	0.00767	CbGpPWpGaD
Lithium—Convulsion—Betamethasone—ankylosing spondylitis	0.00137	0.00167	CcSEcCtD
Lithium—Convulsion—Dexamethasone—ankylosing spondylitis	0.00137	0.00167	CcSEcCtD
Lithium—Discomfort—Dexamethasone—ankylosing spondylitis	0.00133	0.00162	CcSEcCtD
Lithium—Discomfort—Betamethasone—ankylosing spondylitis	0.00133	0.00162	CcSEcCtD
Lithium—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00132	0.00161	CcSEcCtD
Lithium—GSK3B—Immune System—ERAP1—ankylosing spondylitis	0.00131	0.00727	CbGpPWpGaD
Lithium—Vision blurred—Prednisone—ankylosing spondylitis	0.0013	0.00158	CcSEcCtD
Lithium—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.00129	0.00158	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.00129	0.00157	CcSEcCtD
Lithium—Oedema—Betamethasone—ankylosing spondylitis	0.00129	0.00157	CcSEcCtD
Lithium—Oedema—Dexamethasone—ankylosing spondylitis	0.00129	0.00157	CcSEcCtD
Lithium—GSK3B—Innate Immune System—HLA-C—ankylosing spondylitis	0.00129	0.00717	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD79A—ankylosing spondylitis	0.00128	0.0071	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.00127	0.00155	CcSEcCtD
Lithium—Shock—Dexamethasone—ankylosing spondylitis	0.00127	0.00155	CcSEcCtD
Lithium—Shock—Betamethasone—ankylosing spondylitis	0.00127	0.00155	CcSEcCtD
Lithium—GSK3A—Disease—B3GNT2—ankylosing spondylitis	0.00127	0.00706	CbGpPWpGaD
Lithium—Agitation—Prednisone—ankylosing spondylitis	0.00126	0.00154	CcSEcCtD
Lithium—Angioedema—Prednisone—ankylosing spondylitis	0.00126	0.00153	CcSEcCtD
Lithium—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.00125	0.00152	CcSEcCtD
Lithium—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.00125	0.00152	CcSEcCtD
Lithium—Vertigo—Prednisone—ankylosing spondylitis	0.00124	0.00151	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00124	0.00688	CbGpPWpGaD
Lithium—Syncope—Prednisone—ankylosing spondylitis	0.00123	0.0015	CcSEcCtD
Lithium—Tinnitus—Methotrexate—ankylosing spondylitis	0.00123	0.0015	CcSEcCtD
Lithium—Anorexia—Dexamethasone—ankylosing spondylitis	0.00123	0.0015	CcSEcCtD
Lithium—Anorexia—Betamethasone—ankylosing spondylitis	0.00123	0.0015	CcSEcCtD
Lithium—Fatigue—Triamcinolone—ankylosing spondylitis	0.00123	0.00149	CcSEcCtD
Lithium—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00122	0.00149	CcSEcCtD
Lithium—Loss of consciousness—Prednisone—ankylosing spondylitis	0.00121	0.00147	CcSEcCtD
Lithium—Hypotension—Dexamethasone—ankylosing spondylitis	0.0012	0.00147	CcSEcCtD
Lithium—Hypotension—Betamethasone—ankylosing spondylitis	0.0012	0.00147	CcSEcCtD
Lithium—GSK3B—Immune System—CARD9—ankylosing spondylitis	0.00119	0.00665	CbGpPWpGaD
Lithium—Convulsion—Prednisone—ankylosing spondylitis	0.00119	0.00145	CcSEcCtD
Lithium—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00117	0.00143	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00117	0.00143	CcSEcCtD
Lithium—Arthralgia—Prednisone—ankylosing spondylitis	0.00117	0.00143	CcSEcCtD
Lithium—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.00117	0.00143	CcSEcCtD
Lithium—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.00117	0.00142	CcSEcCtD
Lithium—Alopecia—Methotrexate—ankylosing spondylitis	0.00117	0.00142	CcSEcCtD
Lithium—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.00116	0.00141	CcSEcCtD
Lithium—Discomfort—Prednisone—ankylosing spondylitis	0.00116	0.00141	CcSEcCtD
Lithium—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00113	0.00138	CcSEcCtD
Lithium—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00113	0.00138	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—ankylosing spondylitis	0.00113	0.00137	CcSEcCtD
Lithium—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.00112	0.00137	CcSEcCtD
Lithium—Oedema—Prednisone—ankylosing spondylitis	0.00112	0.00137	CcSEcCtD
Lithium—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.00112	0.00137	CcSEcCtD
Lithium—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00112	0.00137	CcSEcCtD
Lithium—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00112	0.00137	CcSEcCtD
Lithium—Fatigue—Betamethasone—ankylosing spondylitis	0.00111	0.00135	CcSEcCtD
Lithium—Fatigue—Dexamethasone—ankylosing spondylitis	0.00111	0.00135	CcSEcCtD
Lithium—Shock—Prednisone—ankylosing spondylitis	0.0011	0.00135	CcSEcCtD
Lithium—Vision blurred—Methotrexate—ankylosing spondylitis	0.00108	0.00132	CcSEcCtD
Lithium—Anorexia—Prednisone—ankylosing spondylitis	0.00107	0.0013	CcSEcCtD
Lithium—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.00106	0.0013	CcSEcCtD
Lithium—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.00106	0.0013	CcSEcCtD
Lithium—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.00105	0.00129	CcSEcCtD
Lithium—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.00105	0.00129	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00104	0.00579	CbGpPWpGaD
Lithium—Vertigo—Methotrexate—ankylosing spondylitis	0.00103	0.00126	CcSEcCtD
Lithium—GSK3A—Innate Immune System—HLA-B—ankylosing spondylitis	0.00103	0.00574	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00102	0.00125	CcSEcCtD
Lithium—Dizziness—Prednisolone—ankylosing spondylitis	0.00102	0.00125	CcSEcCtD
Lithium—Asthenia—Triamcinolone—ankylosing spondylitis	0.00102	0.00124	CcSEcCtD
Lithium—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00102	0.00124	CcSEcCtD
Lithium—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00102	0.00124	CcSEcCtD
Lithium—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00102	0.00124	CcSEcCtD
Lithium—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00102	0.00124	CcSEcCtD
Lithium—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00102	0.00124	CcSEcCtD
Lithium—GSK3A—Immune System—HLA-C—ankylosing spondylitis	0.00101	0.00565	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000998	0.00556	CbGpPWpGaD
Lithium—Convulsion—Methotrexate—ankylosing spondylitis	0.000996	0.00121	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000989	0.00551	CbGpPWpGaD
Lithium—Dyspepsia—Prednisone—ankylosing spondylitis	0.000988	0.0012	CcSEcCtD
Lithium—Arthralgia—Methotrexate—ankylosing spondylitis	0.000979	0.00119	CcSEcCtD
Lithium—Decreased appetite—Prednisone—ankylosing spondylitis	0.000976	0.00119	CcSEcCtD
Lithium—Rash—Prednisolone—ankylosing spondylitis	0.000974	0.00119	CcSEcCtD
Lithium—Dermatitis—Prednisolone—ankylosing spondylitis	0.000973	0.00119	CcSEcCtD
Lithium—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00097	0.00118	CcSEcCtD
Lithium—Fatigue—Prednisone—ankylosing spondylitis	0.000968	0.00118	CcSEcCtD
Lithium—Headache—Prednisolone—ankylosing spondylitis	0.000968	0.00118	CcSEcCtD
Lithium—Discomfort—Methotrexate—ankylosing spondylitis	0.000967	0.00118	CcSEcCtD
Lithium—Confusional state—Methotrexate—ankylosing spondylitis	0.000946	0.00115	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000943	0.00525	CbGpPWpGaD
Lithium—Dizziness—Triamcinolone—ankylosing spondylitis	0.00094	0.00115	CcSEcCtD
Lithium—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000938	0.00114	CcSEcCtD
Lithium—GSK3B—Disease—B3GNT2—ankylosing spondylitis	0.000937	0.00522	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000925	0.00113	CcSEcCtD
Lithium—Asthenia—Dexamethasone—ankylosing spondylitis	0.000925	0.00113	CcSEcCtD
Lithium—Asthenia—Betamethasone—ankylosing spondylitis	0.000925	0.00113	CcSEcCtD
Lithium—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000918	0.00112	CcSEcCtD
Lithium—Nausea—Prednisolone—ankylosing spondylitis	0.000918	0.00112	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000916	0.0051	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CRP—ankylosing spondylitis	0.00091	0.00507	CbGpPWpGaD
Lithium—Vomiting—Triamcinolone—ankylosing spondylitis	0.000904	0.0011	CcSEcCtD
Lithium—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000901	0.0011	CcSEcCtD
Lithium—Rash—Triamcinolone—ankylosing spondylitis	0.000896	0.00109	CcSEcCtD
Lithium—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000895	0.00109	CcSEcCtD
Lithium—Anorexia—Methotrexate—ankylosing spondylitis	0.000895	0.00109	CcSEcCtD
Lithium—Rash—Methylprednisolone—ankylosing spondylitis	0.000894	0.00109	CcSEcCtD
Lithium—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000893	0.00109	CcSEcCtD
Lithium—Headache—Triamcinolone—ankylosing spondylitis	0.00089	0.00109	CcSEcCtD
Lithium—Headache—Methylprednisolone—ankylosing spondylitis	0.000888	0.00108	CcSEcCtD
Lithium—Abdominal pain—Prednisone—ankylosing spondylitis	0.000888	0.00108	CcSEcCtD
Lithium—Body temperature increased—Prednisone—ankylosing spondylitis	0.000888	0.00108	CcSEcCtD
Lithium—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000882	0.00108	CcSEcCtD
Lithium—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000882	0.00108	CcSEcCtD
Lithium—GSK3A—Immune System—IL1RN—ankylosing spondylitis	0.000881	0.00491	CbGpPWpGaD
Lithium—Hypotension—Methotrexate—ankylosing spondylitis	0.000877	0.00107	CcSEcCtD
Lithium—GSK3A—Innate Immune System—TLR4—ankylosing spondylitis	0.000873	0.00486	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000855	0.00104	CcSEcCtD
Lithium—Dizziness—Betamethasone—ankylosing spondylitis	0.000853	0.00104	CcSEcCtD
Lithium—Dizziness—Dexamethasone—ankylosing spondylitis	0.000853	0.00104	CcSEcCtD
Lithium—Nausea—Triamcinolone—ankylosing spondylitis	0.000844	0.00103	CcSEcCtD
Lithium—Nausea—Methylprednisolone—ankylosing spondylitis	0.000842	0.00103	CcSEcCtD
Lithium—Somnolence—Methotrexate—ankylosing spondylitis	0.000834	0.00102	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000826	0.00101	CcSEcCtD
Lithium—Vomiting—Betamethasone—ankylosing spondylitis	0.00082	0.000999	CcSEcCtD
Lithium—Vomiting—Dexamethasone—ankylosing spondylitis	0.00082	0.000999	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000816	0.000994	CcSEcCtD
Lithium—Rash—Betamethasone—ankylosing spondylitis	0.000813	0.000991	CcSEcCtD
Lithium—Rash—Dexamethasone—ankylosing spondylitis	0.000813	0.000991	CcSEcCtD
Lithium—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000812	0.00099	CcSEcCtD
Lithium—Dermatitis—Betamethasone—ankylosing spondylitis	0.000812	0.00099	CcSEcCtD
Lithium—Fatigue—Methotrexate—ankylosing spondylitis	0.000809	0.000986	CcSEcCtD
Lithium—Headache—Betamethasone—ankylosing spondylitis	0.000808	0.000985	CcSEcCtD
Lithium—Headache—Dexamethasone—ankylosing spondylitis	0.000808	0.000985	CcSEcCtD
Lithium—Asthenia—Prednisone—ankylosing spondylitis	0.000806	0.000982	CcSEcCtD
Lithium—GSK3A—Immune System—CD79A—ankylosing spondylitis	0.000774	0.00431	CbGpPWpGaD
Lithium—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000773	0.000943	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000768	0.00428	CbGpPWpGaD
Lithium—Diarrhoea—Prednisone—ankylosing spondylitis	0.000768	0.000936	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000767	0.000935	CcSEcCtD
Lithium—Nausea—Betamethasone—ankylosing spondylitis	0.000766	0.000933	CcSEcCtD
Lithium—Nausea—Dexamethasone—ankylosing spondylitis	0.000766	0.000933	CcSEcCtD
Lithium—GSK3B—Innate Immune System—HLA-B—ankylosing spondylitis	0.000761	0.00424	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-C—ankylosing spondylitis	0.00075	0.00418	CbGpPWpGaD
Lithium—Dizziness—Prednisone—ankylosing spondylitis	0.000743	0.000905	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000742	0.000904	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000742	0.000904	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000731	0.00407	CbGpPWpGaD
Lithium—Vomiting—Prednisone—ankylosing spondylitis	0.000714	0.00087	CcSEcCtD
Lithium—Rash—Prednisone—ankylosing spondylitis	0.000708	0.000863	CcSEcCtD
Lithium—Dermatitis—Prednisone—ankylosing spondylitis	0.000707	0.000862	CcSEcCtD
Lithium—Headache—Prednisone—ankylosing spondylitis	0.000703	0.000857	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000677	0.00377	CbGpPWpGaD
Lithium—Asthenia—Methotrexate—ankylosing spondylitis	0.000673	0.000821	CcSEcCtD
Lithium—GSK3B—Innate Immune System—CRP—ankylosing spondylitis	0.000673	0.00375	CbGpPWpGaD
Lithium—Nausea—Prednisone—ankylosing spondylitis	0.000667	0.000813	CcSEcCtD
Lithium—GSK3B—Immune System—IL1RN—ankylosing spondylitis	0.000651	0.00363	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TLR4—ankylosing spondylitis	0.000645	0.00359	CbGpPWpGaD
Lithium—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000642	0.000783	CcSEcCtD
Lithium—GSK3A—Immune System—IL1A—ankylosing spondylitis	0.000634	0.00353	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD40LG—ankylosing spondylitis	0.000631	0.00351	CbGpPWpGaD
Lithium—Dizziness—Methotrexate—ankylosing spondylitis	0.000621	0.000756	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000609	0.00339	CbGpPWpGaD
Lithium—GSK3A—Immune System—HLA-B—ankylosing spondylitis	0.0006	0.00334	CbGpPWpGaD
Lithium—Vomiting—Methotrexate—ankylosing spondylitis	0.000597	0.000727	CcSEcCtD
Lithium—Rash—Methotrexate—ankylosing spondylitis	0.000592	0.000721	CcSEcCtD
Lithium—Dermatitis—Methotrexate—ankylosing spondylitis	0.000591	0.000721	CcSEcCtD
Lithium—Headache—Methotrexate—ankylosing spondylitis	0.000588	0.000717	CcSEcCtD
Lithium—GSK3B—Immune System—CD79A—ankylosing spondylitis	0.000572	0.00318	CbGpPWpGaD
Lithium—Nausea—Methotrexate—ankylosing spondylitis	0.000557	0.000679	CcSEcCtD
Lithium—GSK3A—Immune System—HLA-A—ankylosing spondylitis	0.000556	0.0031	CbGpPWpGaD
Lithium—GSK3A—Immune System—CRP—ankylosing spondylitis	0.00053	0.00295	CbGpPWpGaD
Lithium—GSK3A—Disease—HLA-A—ankylosing spondylitis	0.000513	0.00286	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR4—ankylosing spondylitis	0.000508	0.00283	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1A—ankylosing spondylitis	0.000469	0.00261	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD40LG—ankylosing spondylitis	0.000466	0.0026	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTGER4—ankylosing spondylitis	0.00045	0.00251	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-B—ankylosing spondylitis	0.000443	0.00247	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP3—ankylosing spondylitis	0.000434	0.00242	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-A—ankylosing spondylitis	0.000411	0.00229	CbGpPWpGaD
Lithium—GSK3B—Immune System—CRP—ankylosing spondylitis	0.000392	0.00218	CbGpPWpGaD
Lithium—GSK3B—Disease—HLA-A—ankylosing spondylitis	0.000379	0.00211	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR4—ankylosing spondylitis	0.000376	0.00209	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—ankylosing spondylitis	0.000345	0.00192	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP3—ankylosing spondylitis	0.000321	0.00178	CbGpPWpGaD
